A

bipartisan bill was introduced in Congress this week in a bid to lower drugs costs for some hospitals, potentially reviving a contentious battle that the pharmaceutical industry appeared to win nearly two years ago.

The legislation would restore a coveted discount for some 1,200 rural hospitals and a handful of cancer-care hospitals when purchasing drugs with so-called orphan designations, which are granted to medicines for treating rare diseases. A court ruling in 2015 had eliminated the price break.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.